ASX Announcement



Australian Clinical Labs Limited

ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia

clinicallabs.com.au

Wednesday, 16 April 2025

Retirement of Mr Michael Alscher

Australian Clinical Labs Limited (ASX: ACL, Company) wishes to inform the market that the Chair of its board of directors, Mr Michael Alscher, will retire as a director with effect from 30 April 2025. Michael has been Chair of ACL and its predecessor company Clinical Labs Pty Ltd since 2015. The Company and its directors wish to express their gratitude to Michael for his leadership and dedication over his tenure as a director and Chair.

The Company is actively engaged in succession planning and ensuring that the composition and skill set of its board supports ACL's future strategy and operations. Mr Mark Haberlin, the Chair of ACL's Audit and Risk Committee, will be appointed as Interim Chair of the board following Michael's retirement. Mark joined ACL as a non-executive director on its IPO in April 2021 and as a former partner of PwC has over 25 years' experience in audit, risk management, capital transactions and mergers and acquisitions across a range of industries, including healthcare. Mark is currently the lead independent director of Abacus Property Group and chairs its audit and risk committee.

- ENDS -

This announcement was authorised for release to ASX by the Company Secretary of ACL. For further information regarding this announcement, please contact:

Company Secretary

Eleanor Padman Company Secretary Email:

epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.